8.2 C
London

Amira Bennett

Investigative reporter, focus on human rights and the Middle East

Aleria Launches UAE’s First NVIDIA DGX Spark, Advancing Sovereign AI Leadership

Aleria launches NVIDIA DGX Spark in the UAE, becoming the first organisation in the country to receive and deploy this compact AI supercomputer. This strategic milestone marks a major step in the UAE’s sovereign AI ambitions and solidifies the...

Datavault AI Launches Data Unions to Tokenise Insurance and Accounting Data

Datavault AI Launches Data Unions with the objective of tokenising anonymised insurance and accounting data to generate new revenue streams for independent operators. The company is partnering with key industry networks to transform large data markets into recurring‑income opportunities. Strategic Initiatives...

The US and DRC Seal a Long-Term Economic Partnership

The long-term economic partnership between the United States and the Democratic Republic of Congo, formalised at the U.S.–DRC Economic Forum in Washington, marks a strategic turning point in Africa's economic landscape. Far from being a routine investment event, this...

Aleria-NVIDIA Alliance Drives UAE’s Sovereign AI Ambitions

The Aleria-NVIDIA collaboration is propelling the UAE’s national vision for sovereign artificial intelligence and cloud infrastructure. Through the integration of advanced computing and a powerful Super App, this initiative champions data independence and AI-led transformation. High-Performance Infrastructure for a Sovereign...

FOBI AI 3.0 Launches as Integrated AI Consulting & Execution Platform

FOBI AI 3.0 is officially unveiled, representing the company’s ambition to merge strategy, technical architecture and execution into a cohesive AI‑native service model. This launch underscores Fobi’s push to scale through an integrated delivery framework (keyphrase used). Market Dynamics &...

Tourmaline Bio Acquisition by Novartis – A $1.4 Billion Cardiovascular Bet

Tourmaline Bio Acquisition by Novartis signals a pivotal acceleration in cardiovascular innovation. In a cash transaction valued at $1.4 billion, the Swiss pharmaceutical giant is acquiring Tourmaline Bio (NASDAQ: TRML) for $48.00 per share, a 59% premium over its...
spot_img

latest articles